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Bladder urothelial cell carcinoma (UCC) is an increasingly prevalent cancer worldwide, and thus, gaining 
a better understanding of its identifiable risk factors is a global priority. This study addressed this public 
health need with the understanding that cancer-initiating events, such as chromosome breakage, 
loss and rearrangement, can be reasonably used as biomarkers to evaluate an individual’s cancer risk. 
Overall, forty bladder cancer patients and twenty controls were evaluated for genomic instability. To 
the best of the investigators’ knowledge, this is the first study to perform micronucleus (MN) assays 
simultaneously in urothelial exfoliated cells (UEC), buccal exfoliated cells (BEC), and peripheral blood 
lymphocytes (PBL) in first-diagnosed, non-smoker bladder UCC patients. Additionally, the frequency of 
nucleoplasmic bridges (NPBs) and nuclear buds (NBUDs) in PBL was evaluated. The MN frequencies in 
UEC, BEC, and PBL, as well as the frequencies of NPBs and NBUDs, were significantly higher in patients 
than in controls. In conclusion, MN assays, particularly in UEC, may be used to identify individuals 
who are at high risk of developing UCC, as single or as additional triage test to UroVysion FISH test. 
Our results further validate the efficacy of biomarkers, such as MN, NPBs, and NBUDs, as predictors of 
genomic instability.
Bladder urothelial cell carcinoma (UCC) has become a globally common cancer, with an estimated 430000 new 
cases diagnosed in 2012, and it has a higher incidence rate in men than in women1 and increased frequency in 
industrial areas2 and in people exposed to arsenic3, cigarette smoking, alcohol, and so on4. Typically, UCC pre-
sents with haematuria, and 75% of patients with UCC initially have non-muscle invasive urothelial carcinoma 
(NMIUC, Ta), of low or high grade, with a high chance of recurrence (~60%) and long-term patient surveillance5. 
UCC is associated with aneuploidy (tetrasomy) of chromosomes 3, 7, and 17 as well as a loss of 9p216. Cystoscopy 
is the gold standard for the detection of bladder tumours, followed by urine cytology and the UroVysion™ (Vysis, 
Downers Grove, IL) FISH test7. Except for cytology, other methods, although they have high detection rates, are 
expensive, time consuming and uncomfortable8.
The integrity or completeness of genomic information is a fundamental pre-requisite for life. In human 
tumour cells, some of one or more of the cell’s protective mechanisms are disrupted, and consequently, the cell’s 
genomic integrity is compromised9. Chromosomal instability (CIN) is a hallmark cause of the aneuploidy that is 
observed in most solid tumour cells and is often associated with the missegregation of chromosomes that results 
from improper kinetochore-microtubule attachments and the consequent presence of lagging chromosomes dur-
ing anaphase10–12. Chromosome breakage, loss and rearrangement are important initiating events in cancer13, 
and thus, the use of biomarkers of chromosomal damage, such as micronuclei (MN), nucleoplasmic bridges 
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(NPBs) and nuclear buds (NBUDs), to predict cancer risk and identify high-risk individuals is both valuable and 
imperative9.
MNi are defined as small chromatinic bodies that appear in the cell cytoplasm and originate from acentric 
chromosome fragments (particularly from chromosomes 1, 9 or 16), acentric chromatid fragments or whole 
chromosomes (generally sex chromosomes, especially the X chromosome) and that fail to be included in the 
daughter nuclei at the completion of telophase during mitosis14. The MN frequency appears to increase in 
carcinogen-exposed tissues long before any clinical symptoms are evident15. The MN frequency is measured by 
the MN assay, usually reported as the number of cells containing MNi per total cells counted. This assay was first 
used in exfoliated cells by Stich et al.16.
Among the changes that can occur within DNA, point mutations are the most likely to accumulate, survive, 
and result in tumour formation in cells that proliferate and regenerate17. More than 90% of cancers arise in epi-
thelial tissues, and exfoliated epithelial cells have traditionally been used for cancer screening and monitoring by 
cytopathologists. These cells have a high turnover rate; within 1–3 weeks, they exfoliate along with any chromo-
somal damage (MN) to basal cells in their places of origin16. The MN assay of exfoliated cells is a cost-effective, 
non-invasive method that uses the formation of an MN in exfoliated cells of organs such as the oral cavity, nasal 
cavity, bladder, cervix, and oesophagus as an endpoint to detect endogenous, lifestyle, occupational and environ-
mental exposures18.
Further application of the MN frequency to peripheral blood lymphocytes (PBL) is also used extensively 
in molecular epidemiology and cytogenetics19. The DNA damage events in PBL are specifically scored in 
once-divided binucleated (BN) cells that have completed nuclear division but have been blocked at the binu-
cleated stage prior to cytokinesis. The events scored include the following: MNi (a biomarker of chromosome 
breakage and/or whole chromosome loss), NPBs (a biomarker of DNA misrepair and/or telomere end-fusions) 
and NBUDs (a biomarker of the elimination of amplified DNA and/or DNA repair complexes)20.
The presence of an association between MN induction and cancer development is supported by a number 
of observations19,21–23. It has been postulated that exfoliated mucosa cells have a high predictive value for the 
detection of carcinogenesis since the majority of human tumours are of epithelial origin24. Cultured cells are not 
needed to perform an MN assay in exfoliated cells, and its noninvasive quality makes the assay an attractive can-
didate for biomonitoring human populations or individuals25.
The aim of this study was to evaluate genomic instability in bladder UCC patients by performing MN assays in 
UEC and BEC and by performing a cytokinesis-block micronucleus (CBMN) cytome assay in PBL, all of which 
are performed simultaneously in first-diagnosed patients. Furthermore, this study will assess the frequencies of 
MNi, NPBs and NBUDs according to tumour muscle invasion, tumour grade, stage and recurrence.
Results
The characteristics of the study population are shown in Table 1. The MN frequencies in UEC, BEC and PBL in the 
patient group (n = 40) were about 17 times higher, 3 times higher, and 4 times higher, respectively, than the MN 
frequencies in UEC, BEC, and PBL in the control group (n = 20) (Fig. 1a–c). Furthermore, the NPB and NBUD 
frequencies in PBL in the patient group were 10 times higher and 12 times higher, respectively, than in the control 
group (Fig. 1d,e). Since study variables didn’t follow a normal distribution (tested by Kolmogorov-Smirnov test), 
Covariates Cases (%) Controls
Number 40 20
NMIUC 16 (40%) —
MIUC 24 (60%) —
Age range 37–78 yrs 31–72 yrs
Smoking status Non-smokers Non-smokers
T stage —
Ta 15 (37%) —
T1 14 (35%) —
T2 8 (20%) —
T3 1 (2.5%) —
T4 2 (5%) —
Tis — —
Tx — —
Grading (WHO 2004)* —
Low grade 20 (50%) —
High grade 20 (50%) —
Recurrence —
Recurrent 12 (30%) —
Non-recurrent 28 (70%) —
Table 1. Baseline characteristics of bladder urothelial carcinoma patients and controls. Abbreviations: NMIUC –
Non-muscle invasive urothelial carcinoma; MIUC- Muscle invasive urothelial carcinoma. *For reference see: Eble 
JN et al. Pathology and genetics of tumors of the urinary system and male genital organs, (2004).
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non-parametric tests were employed to verify differences among groups: Man-Whitney U test was applied to see 
the differences between two independent groups, and Spearman’s correlation was applied to show the relationship 
between study variables.
According to Man Whitney U test, statistically significant differences were found in all study variables when 
the patient group (n = 40) was compared to the control group (n = 20) (p < 0.001; Table 2).
Spearman’s rank correlation showed no significant correlation between study variables in the control group 
(Table 3). However, in the patient group (Table 3), it showed: moderate positive relationships between the MN 
frequencies in UEC and BEC (rho = 0.427, p = 0.006); between the MN frequencies in BEC and PBL (rho = 0.382, 
p = 0.015), and between the MN frequency in PBL and the NPB frequency in PBL (rho = 0.327, p = 0.040). 
Furthermore, Spearman’s correlation showed a strong positive relationship between the frequencies of NPBs and 
NBUDs in PBL (rho = 0.701 and p < 0.001). There was a positive increasing trend for the relationship between the 
MN and NBUD frequencies in PBL, but it did not reach the level of statistical significance (Table 3).
Statistically significant differences were found in all study variables when patients, stratified by tumour grade 
into the low grade (n = 20) and high grade (n = 20) subgroups, were compared between one another (p < 0.05; 
Table 4). Different results were observed when patient subgroups, stratified by tumour muscle invasion into 
non-muscle invasive urothelial carcinoma (NMIUC, n = 16) and muscle invasive urothelial carcinoma (MIUC, 
n = 24), were compared: only MN frequencies in UEC were statistically significant (p < 0.044) between these 
subgroups, whereas MN frequencies in BEC, PBL, as well as NPB and NBUD frequencies in PBL didn’t reach the 
level of statistical significance (p > 0.05 in all cases, Table 5).
Within the MIUC subgroup, Spearman’s rank correlation showed a greater correlation between study var-
iables than it did in other subgroups. In the MIUC subgroup (Table 3), a moderate positive relationship was 
found between the MN frequencies in BEC and PBL (rho = 0.478, p < 0.018); between the MN frequency in 
PBL and NPB frequency in PBL (rho = 0.552, p < 0.005); and between the frequencies of MN and NBUD in PBL 
(rho = 0.450, p < 0.027), whereas a strong positive relationship was found between the NPB and NBUD frequen-
cies in PBL (rho = 0.622, p < 0.001). Further, in the NMIUC subgroup a strong positive correlation was found 
Figure 1. Box plots showing MN frequencies in: (a) UEC, (b) BEC and (c) PBL, as well as (d) NPB and (e) 
NBUD frequencies in PBL in the control group, low grade and high grade patient groups.
Mean rank 
UCC
Mean rank 
control U z p value z adjusted p value
Two-sided 
exact p value
MN in UEC 40.33 10.85 7.0 6.155 <0.001 6.202 <0.001 <0.001***
MN in BEC 38.04 15.43 98.5 4.720 <0.001 4.739 <0.001 <0.001***
MN in PBL 39.41 12.68 43.5 5.583 <0.001 5.638 <0.001 <0.001***
NPBs in PBL 36.66 18.18 153.5 3.858 <0.001 4.105 <0.001 <0.001***
NBUDs in PBL 37.50 16.50 120.0 4.383 <0.001 4.594 <0.001 <0.001***
Table 2. Mann-Whitney U test (with continuity correction) between UCC patients (n = 40) and controls 
(n = 20). ***p < 0.001.
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only between the NPB and NBUD frequencies in PBL (rho = 0.861, p < 0.000), whereas between other variables 
no significant correlations were found (Table 3). According to the tumour grade, within the low grade subgroup 
a positive correlation was found between the MN frequencies in UEC and BEC (rho = 0.468, p < 0.038), as well 
as between the NPB and NBUD frequencies in PBL within the low grade subgroup and the high grade subgroup 
(rho = 0.579, p < 0.007; rho = 0.710, p < 0.000, respectively; Table 3).
Finally, when MNi in UEC, BEC and PBL, as well as NPBs and NBUDs, were correlated to the tumour stage 
and the tumour recurrences, we found that among all of these variables, only the MN frequency in PBL showed 
a positive trend of correlation with the tumour stage (rho = 0.276, p < 0.085), but it did not reach the level of 
statistical significance (data not shown).
Discussion
It is well established that cancer has a genetic basis. Cancer development is a multistep process that involves the 
progressive accumulation of DNA damage, leading to the activation of oncogenes and to the loss of tumour sup-
pressor functions, which in turn, result in changes in cell function and in the transformation of cells into malig-
nant cells26. The search for cytogenetic biomarkers for the identification of groups and individuals who are at high 
risk of developing cancer is an important initiative in public health. By identifying and validating the markers for 
cancer risk, the global community can improve disease outcomes and increase the frequency of early diagnoses. 
In this research project, we used the MN assay in UEC and BEC and the CBMN cytome assay in PBL to evaluate 
genomic instability in bladder UCC patients. To the best of our knowledge, this is the first study performed on all 
three cell types of first-diagnosed non-smoker bladder cancer patients.
Two previous studies performed MN assays in three types of cells (UEC, BEC and PBL) to evaluate those cells 
in individuals exposed to arsenic exposure27 and cigarette consumption28, but none in cancer patients. These stud-
ies reported a slight increase in the prevalence of micronuclei in lymphocytes compared to exfoliated epithelial 
MN in UEC:  
MN in BEC
MN in UEC:  
MN in PBL
MN in BEC:  
MN in PBL
MN in 
PBL: NPB
MN in PBL: 
NBUD
NPB: 
NBUD
Control group (n = 20) rhop
−0.091
0.702
0.082
0.732
0.264
0.261
0.049
0.831
0.049
0.837
−0175
0.459
Patients (n = 40) rhop
0.427*
0.006
0.197
0.224
0.382*
0.015
0.327*
0.040
0.271
0.091
0.701*
0.000
NMIUC (n = 16) rhop
0.421
0.104
0.018
0.947
0.245
0.361
−0.093
0.731
−0.194
0.472
0.861*
0.000
MIUC (n = 24) rhop
0.343
0.100
0.141
0.511
0.478*
0.018
0.552*
0.005
0.450*
0.027
0.622*
0.001
Low grade (n = 20) rhop
0.468*
0.038
0.277
0.236
0.328
0.158
0.039
0.871
0.055
0.818
0.579*
0.007
High grade (n = 20) rhop
0.213
0.367
−0.163
0.492
0.339
0.144
0.185
0.435
−0.180
0.447
0.710*
0.000
Table 3. Spearman’s correlation of the MN frequencies in UEC, BEC and PBL and the NPB and NBUD 
frequencies in PBL in the control group, all cases group, the NMIUC and MIUC subgroups and the low and 
high grade subgroups. *Statistically significant positive correlation.
Mean rank 
Low grade
Mean rank 
High grade U z p value z adjusted p value
Two-sided 
exact p value
MN in UEC 16.88 24.13 127.5 −1.948 0.051 −1.954 0.051 0.049*
MN in BEC 15.65 25.35 103.0 −2.610 0.009 −2.620 0.009 0.008**
MN in PBL 13.98 27.03 69.5 −3.517 0.000 −3.554 0.000 <0.001***
NPBs in PBL 14.58 26.43 81.5 −3.192 0.001 −3.258 0.001 0.001**
NBUDs in PBL 15.00 26.00 90.0 −2.962 0.003 −3.010 0.003 0.002**
Table 4. Mann-Whitney U test (with continuity correction) between UCC low grade (n = 20) and UCC high 
grade (n = 20) patients. *p < 0.05; **p < 0.01; ***p < 0.001.
Mean rank 
MIUC
Mean rank 
NMIUC U z p value z adjusted p value
Two-sided 
exact p value
MN in UEC 23.52 15.97 119.5 1.988 0.047 1.994 0.046 0.044*
MN in BEC 22.15 18.03 152.5 1.077 0.282 1.081 0.280 0.279
MN in PBL 22.44 17.59 145.5 1.270 0.204 1.283 0.199 0.202
NPBs in PBL 21.42 19.13 170.0 0.594 0.553 0.606 0.545 0.557
NBUDs in PBL 22.17 18.00 152.0 1.091 0.275 1.108 0.268 0.279
Table 5. Mann-Whitney U test (with continuity correction) between subgroups stratified according to tumour 
muscle invasion: MIUC (n = 24) and NMIUC (n = 16). *p < 0.05.
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cells. However, those results may be confounded by the discrepancy in the turnover rates of these two cell types, 
with lymphocytes exhibiting a longer lifespan than epithelial cells29. In our observation, different MN means were 
found among the three cell types in patients with developed UCC. Specifically, exfoliated cells (UEC and BEC) 
had a greater prevalence of MN than PBL. Recently, there has been a growing emphasis on the value of utilizing 
the MN assay in exfoliated cells as a method for the early detection and/or monitoring of cancer patients, as well 
as the evaluation of different exposures, due to the method’s cost effectiveness and non-invasiveness30,31.
Given that epithelial cells are highly proliferative and that they represent the origin of more than 90% of all 
human cancers32, it is evident that epithelial cells represent a reasonable alternative to PBL for biomonitoring 
studies. Furthermore, while CBMN in PBL requires cell culturing, isolation of UEC can be accomplished via 
urine sample centrifugation alone. In the approximately thirty years since epithelial cells from human urine were 
first used for MN analyses, approximately 56 studies have been published30, most of which were performed to 
predict the risk of UCC based on the presence of MN-promoting genotoxic metabolites in urothelial cells.
Our results show that the MN frequency in UEC is significantly higher in patients with UCC than in individ-
uals in the control group as well as between subgroups according to tumour grade and the tumour muscle inva-
sion. Several confounding factors (lifestyle habits (smoking, alcohol, etc.), age, exposure to mutagen agents) may 
modulate MN formation and frequency33, but the abovementioned association in our study was independent of 
these factors, suggesting that endogenous factors are likely to be the most relevant causative factors that contrib-
ute to DNA damage in UCC. This result agrees with a previous study that phenotypically profiled urothelial cells 
in patients with a prior history of UCC34. Similarly, the results of a separate previous study indicated that the MN 
frequency in urothelial cells from bladder washings of patients with a history of UCC was higher than that of the 
control group35. Furthermore, in a retrospective study of urine samples, slides that had been identified as atypical 
urothelial cells and subsequently diagnosed as UCC positive were found to be positive for MN. By contrast, slides 
from the control group did not contain MN36. Based on our findings and those of these aforementioned studies, 
it can be concluded that subjects who are at high risk for UCC, who have UCC, or who have a history of UCC 
harbour and accumulate genetically unstable cells in the bladder urothelium, which may represent early precur-
sors of new UCC or subclones from previous UCC35. Lastly, it can be deduced that these changes can be readily 
detected via an MN assay performed on urine.
Use of the MN assay in buccal cells is a well-established and standardized method37 that has been widely 
used in biomonitoring processes. In the present study, observation of the MN frequency in buccal mucosa cells 
revealed significantly higher levels of genomic instability in patients with UCC than in controls, similar to what 
was found in PBL and UEC. The MN frequency in BEC was found to have a statistically significant positive corre-
lation with UEC and PBL in the patient group (p < 0.006, p < 0.015, respectively; Table 3). While there is a lack of 
literature studying the MN frequency in BEC among bladder cancer patients, a number of papers have explored 
the MN frequency in BEC among patients with head and neck cancer9, oral cancer38, breast cancer, and uterine 
cancer39, as well as among those with cervical pre-cancer and cancer40,41. These studies are consistent with our 
findings, showing that the MN index in PBL is significantly reflected by the MN assay in oral exfoliated epithelial 
cells.
The CBMN assay is a genotoxicity assay (methodology) that provides information on a variety of endpoints 
that reflect chromosomal breakage and rearrangements as well as gene amplification21. Measurement of the MN 
frequency in PBL is extensively used in molecular epidemiology and cytogenetics to evaluate the presence and 
extent of chromosomal damage in human populations exposed to genotoxic agents22. PBL circulate and accu-
mulate DNA damage over their lifespans due to their close contact with different tissue microenvironments or 
tumour-derived substances. Thus, chromosomal aberrations in PBL are considered to be valuable biomarkers of 
genomic instability and predictors of cancer risk42.
The association between the MN frequency in PBL and cancer risk is supported by a number of observa-
tions19,23. The HUMN International Collaborative Project suggested that increased MN formation is associated 
with early events in carcinogenesis19.
In this study, the MN frequency in PBL in UCC patients was significantly higher than that in healthy subjects, 
confirming the results of Pardini et al., who found a higher frequency of MN in PBL and an increased frequency 
of NPBs and NBUDs in patients than in controls. Moreover, they found a statistically significant difference 
between non-muscle invasive UCC patients with controls but not between controls and muscle invasive UCC 
patients nor among tumour grades and recurrence23. In contrast, the present study found statistically significant 
differences in the MN, NPB and NBUD frequencies in PBL when comparing the two subgroups (according to 
tumour grade) between one another, but not when these variables were compared between subgroups according 
to tumour muscle invasion.
An increased MN frequency may be considered to be a biomarker of chromosome loss and/or breakage, 
whereas other anomalies, such as NBUDs, are biomarkers of gene amplification and/or the removal of unresolved 
DNA repair complexes, and NPBs are biomarkers of DNA misrepair and/or telomere end-fusions43. The increased 
nuclear anomalies in PBL and BEC indicate that the induction of chromosomal damage employs similar mech-
anisms in different tissues and that the levels of DNA damage measured in surrogate tissues may reflect those 
present in cancer-prone tissues43,44. It is estimated that each human cell is subjected to 70000 lesions per day45 as a 
result of exogenous and endogenous factors. Because the majority of DNA repair pathways are eliminated, these 
important pathways can be inactivated due to the action of such factors, leading to genomic instability, which in 
turn causes an increase in the gene mutation rate at other genomic sites and leads to cellular transformations46. 
Furthermore, abnormal active tumour substances leak from cell membranes and may enter blood circulation and 
interact with other tissues, destabilizing the genome.
The increased MN frequency in the PBL of UCC cases compared with that of controls could be interpreted 
as an altered status of the DNA damage repair system or to reflect an unknown past exposure23. Although our 
patients were non-smokers and non-alcohol consumers and they denied any professional exposure, we cannot 
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rule out other unknown confounding factors that might have an impact on their genomic instability. There are 
contradictory end points after a number of investigations performed in NATO soldiers who served in the Kosovo 
war regarding the effect of the weapons of war, especially those with depleted uranium, on cancer risk elevation. 
A Norwegian investigation showed a 5-fold increase in the incidence of bladder cancer among soldiers who 
served in Kosovo compared with the general Norwegian population47. Other studies show an increased number 
of cancer and MN frequencies in the Bosnian population in regions exposed to depleted uranium during the 
Bosnian war48,49. In Kosovo, there is no investigation that shows the level of contamination with such agents, so 
this hypothesis remains at the level of speculation and should be investigated in the future.
Chromosomal instability correlates with tumour metastasis, but it remains unclear whether it is merely a 
bystander or a driver of metastatic progression50. In our study, the nonsignificant differences in variables (except 
for UEC) between subgroups (NMIUC and MIUC) reveal that the invasive feature of the tumour is likely not 
directly linked with the level of CIN. It is known that higher tumour grades harbour higher levels of CIN, but it is 
also known that low-grade and high-grade UCC can both be invasive. Therefore, there may be other mechanisms 
that generate invasive clones within UCC51,52 in a persistent established state of CIN.
Our data indicate that in UCC, a systemic genomic destabilization occurs and that it can be easily detected 
using the MN assay in UEC, BEC and PBL, which means that these cells reflect the CIN in the UCC state.
Bladder cancer continues to be challenging to detect and treat. Early diagnosis, prior to muscle invasion, can 
greatly impact the clinical outcome, whether measured by disease-specific survival, morbidity, or quality-of-life 
variables53. While cystoscopy and cytology are established standards, the UroVysion™ FISH test is a new but 
expensive and technically demanding approach that focuses on chromosomal aneuploidy using fluorescent in situ 
hybridization (FISH)54 and is mainly used as a surveillance test for NMIUC patients.
It is well recognized that high pre-diagnostic levels of MN are associated with an elevated risk for cancer devel-
opment. It is also known that tetrasomy of chromosomes 3, 7 and 17 and loss of 9p21 can be detected in urine 
samples 1–3 years before diagnosis11. Although more extensive studies are needed, we recommend the following 
practical approach for cancer screening: combined testing for bladder cancer, in which the MN assay in UEC 
might serve as a triage-test for the identification of people who are at high risk for bladder cancer so that they can 
be referred for UroVysion™ FISH testing. This method could reduce the number of unnecessary tests.
In conclusion, our data show that genomic instability can be detected through the MN assay in target cells 
(UEC) as well as in surrogate cells (BEC and PBL). The extent of DNA damage varies among the three cell types, 
but their simultaneous appearance suggests that similar mechanisms can cause a systemic genomic instability in 
different types of cells during carcinogenesis. Although further studies are needed for standardization, our find-
ings support the data in the field that indicate that the MN frequency in exfoliated cells (especially in UEC) may 
be a potential biomarker for the early detection of bladder cancer and for patient surveillance. The MN frequency 
in exfoliated cells might also be able to be used as an additional triage test prior to the UroVysion™ FISH test.
Strengths and limitations. This study used a very homogenous sample. The inclusion criteria for eligibil-
ity, especially the non-smoking status, made the sample collection phase to be a long and a challenging process, 
that resulted in a relatively small sample size. Despite this, the study is valuable as an explorative one, significantly 
pointing the presence of a systemic genomic instability due to bladder cancer disease. Although, further studies 
are needed to set up or to standardize MN frequencies in UEC, BEC, PBL as well as NPBs and NBUDs in PBL, to 
be routinely included as predictive diagnostic criteria for bladder cancer early diagnosis, and cancer surveillance.
Subjects and Methods
Subjects. The study sample consisted of 60 male participants. Subjects were divided into two groups as 
follows:
 1. Patient group – 40 patients diagnosed with bladder UCC.
 2. Control group - 20 healthy men.
This study was conducted at the Urology Clinic and Institute of Pathology of the University Clinical Center of 
Kosovo (UCCK) and Department of Biology, Faculty of Natural Sciences, University of Pristina “Hasan Prishtina”. 
The investigated patients were collected prospectively from 2014 to 2017. The age range of the patient group was 
37 to 78, while the controls were between 31 and 72 years of age.
To be chosen for this study, each prospective subject was required to conform to the following criteria: 
non-smoker, non-alcohol consumer, and no history of chemo- or radiotherapy, as confounding factors4,55–58.
Patients were first verbally briefed regarding the purposes of the study and were introduced to the sample 
collection procedure. Afterwards, patients were asked to provide information regarding their relevant personal 
information (name, age, occupation), family data (diseases with familiar predispositions) and medical data (pres-
ent diseases, past diseases, habits). Informed written consent for sample collection was also obtained from each 
participant. The following three tissue samples were taken from all participants prior to the operation and diag-
nosis: urine, buccal mucosa exfoliated cells and blood.
This research was approved by the Scientific Ethical Committee of UCCK (Nr. 566, date: 7 February 2012). All 
methods were performed in accordance with the relevant guidelines and regulations.
Methods. MN assay in UEC. Midstream urine of the second or third void of the day was requested from 
each participant. The urine was collected in sterile urine containers and was processed within two hours. The 
volume of the voided urine ranged from 150–200 ml.
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Urine samples were transferred to centrifuge tubes and centrifuged at 2000 rpm for 15 min. The supernatant 
was then discarded without disturbing the pellets of urothelial cells. The pellets were washed twice with 0.9% 
NaCl and centrifuged. Cell suspensions were spread onto clean, preheated (40 °C) glass slides and allowed to air 
dry for 5–10 min. The slides were fixed in Carnoy I fixative (methanol: glacial acetic acid, 3:1) at 0 °C for 20 min 
and air dried. The slides were stained with May-Grunwald’s stain (0.25%) for 5 min, counterstained with Giemsa 
(4%) for 10 min and mounted in DPX. Four slides were prepared for each individual.
Following the method of Reali et al.59 and Fortin et al.60, at least 1,000 urothelial cells per individual were ana-
lysed under a light microscope and confirmed by a second observer (Fig. 2a,b).
MN assay in BEC. Buccal exfoliated cells were prepared and analysed after the method of Thomas et al.37 and 
Tolbert et al.61. First, subjects removed unwanted debris from their oral cavities using a distilled water rinse. BEC 
were then obtained by rolling a cytobrush against the buccal mucosa ten times in a circular motion. Next, the 
heads of the brushes were individually placed into separate 30 ml yellow-top containers, each of which contained 
a mixture of the following components: buccal cell buffer (0.01 M Tris-HCl; Sigma T-3253), 0.1 M EDTA tetraso-
dium salt (Sigma E5391), and 0.02 sodium chloride (Sigma S5886) at pH 7.0. The containers were then agitated to 
disperse cells. Cells were transferred into separate TV-10 centrifuge tubes and centrifuged for 10 min at 1500 rpm 
(MSE Mistral 2000). Slides containing two spots of cells were air dried for 10 min and then fixed in ethanol:acetic 
acid (3:1) for 10 min. Slides were then air dried for 10 min prior to staining with Giemsa (5%). At least four slides 
were prepared per individual, and 2,000 cells were analysed per case. The results are expressed as the number of 
micronucleated cells per 1000 counted cells (‰).
All the scoring criteria for observing these nuclear anomalies (Fig. 2c) were taken from the corrected version 
of the Protocol of Thomas and Fenech37.
CBMN cytome assay in PBL. Blood samples (5 ml) were collected via venipuncture into vacutainer blood tubes 
containing a lithium heparin anticoagulant (BD Plymouth. Pl6 7BP. UK). Whole heparinized blood (0.5 ml) was 
added to 5 ml of complete PB-Max Karyotyping medium for cell cultivation (Invitrogen, California, USA). All 
cultures were duplicated and incubated at 37 °C for up to 72 hours. Cytochalasin B (Sigma, St Louis, MO, USA) at 
a final concentration of 4 μg/mL was added 44 hours after the incubation was initiated. The cells were centrifuged 
(Sigma, Germany) at 800 rpm for 10 min and treated with a hypotonic solution (0.075 M KCl). The cell suspension 
was then fixed in Carnoy I fixative (methanol:acetic acid, 3:1) three times and centrifuged (300 g/8 min) after each 
fixation. Finally, the centrifuged cells were resuspended in a small volume of fixative and spread onto specially 
prepared, cold, and lamp-dried slides. The slides were stained with Giemsa solution (5%). At least six slides per 
individual were prepared. Finally, using a light microscope, the MNi, NPBs and NBUDs in PBL (Fig. 2d–f) were 
scored independently by two scorers for 1000 binucleated cells (500 per culture) according to the method of 
Fenech20.
Figure 2. Representative images showing nuclear anomalies observed in the three types of cells: (a,b). 
micronuclei in urothelial cells (arrows), (c) micronucleus in buccal cells (arrow), (d) normal binuclear 
lymphocyte (empty arrow); binuclear lymphocyte with a micronucleus (arrow), (e) nucleoplasmic bridge in 
peripheral blood lymphocytes (arrow), (f) nuclear bud in peripheral blood lymphocytes, (magnification x400).
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Microscopic analyses and photography were performed with an Olympus CX43 light microscope with a 
Moticam 10+, 10.0 MP camera.
Statistical analysis. Since the study variables (the frequency of MN in UEC, BEC and PBL as well as NBUD and 
NPB in PBL) did not follow normal distribution (tested by Kolmogorov-Smirnov test), non-parametric methods 
were used. Mann-Whitney U test was applied for comparison of two independent groups. Correlation analysis 
between study variables were calculated as Spearman’s rank correlation coefficients. All the analyses were per-
formed by Statistica (data analysis software system), version 13 (TIBCO Software Inc. (2018). The results were 
expressed as mean ± standard deviation (SD). A value of p < 0.05 was considered statistically significant.
Data Availability
All data generated or analysed during this study are included in this manuscript.
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